114 related articles for article (PubMed ID: 27111337)
21. Discovery of Clinically Used Octenidine as
Chen XC; Tang GX; Dai J; Dai LT; Wu TY; Li WW; Ou TM; Huang ZS; Tan JH; Chen SB
J Med Chem; 2023 Apr; 66(7):5171-5184. PubMed ID: 36961300
[TBL] [Abstract][Full Text] [Related]
22. Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN.
Packer L; Pavey S; Parker A; Stark M; Johansson P; Clarke B; Pollock P; Ringner M; Hayward N
Carcinogenesis; 2006 Sep; 27(9):1778-86. PubMed ID: 16571650
[TBL] [Abstract][Full Text] [Related]
23. PTEN Methylation Dependent Sinonasal Mucosal Melanoma.
Lee SH; Roh MR; Kang B; Park KH; Kim SH; Lee SE; Rha SY
Cancer Res Treat; 2016 Apr; 48(2):853-8. PubMed ID: 25797573
[TBL] [Abstract][Full Text] [Related]
24. Melanoma mystery.
Davis RJ
Elife; 2017 Jan; 6():. PubMed ID: 28100393
[TBL] [Abstract][Full Text] [Related]
25. Phosphatidylinositol 3'-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN.
Hartmann W; Digon-Söntgerath B; Koch A; Waha A; Endl E; Dani I; Denkhaus D; Goodyer CG; Sörensen N; Wiestler OD; Pietsch T
Clin Cancer Res; 2006 May; 12(10):3019-27. PubMed ID: 16707597
[TBL] [Abstract][Full Text] [Related]
26. PREX2 promotes the proliferation, invasion and migration of pancreatic cancer cells by modulating the PI3K signaling pathway.
Yang J; Gong X; Ouyang L; He W; Xiao R; Tan L
Oncol Lett; 2016 Aug; 12(2):1139-1143. PubMed ID: 27446408
[TBL] [Abstract][Full Text] [Related]
27. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors.
Hou P; Ji M; Xing M
Cancer; 2008 Nov; 113(9):2440-7. PubMed ID: 18831514
[TBL] [Abstract][Full Text] [Related]
28. Somatic mutations of PREX2 gene in patients with hepatocellular carcinoma.
Yang MH; Yen CH; Chen YF; Fang CC; Li CH; Lee KJ; Lin YH; Weng CH; Liu TT; Huang SF; Teh BT; Chen YA
Sci Rep; 2019 Feb; 9(1):2552. PubMed ID: 30796242
[TBL] [Abstract][Full Text] [Related]
29. Methylation of RASSF1A, RASSF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma.
Huang KH; Huang SF; Chen IH; Liao CT; Wang HM; Hsieh LL
Clin Cancer Res; 2009 Jun; 15(12):4174-80. PubMed ID: 19509163
[TBL] [Abstract][Full Text] [Related]
30. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
Fang J; Ding M; Yang L; Liu LZ; Jiang BH
Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033
[TBL] [Abstract][Full Text] [Related]
31. Treatment of NRAS-mutant melanoma.
Johnson DB; Puzanov I
Curr Treat Options Oncol; 2015 Apr; 16(4):15. PubMed ID: 25796376
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
Philip CA; Laskov I; Beauchamp MC; Marques M; Amin O; Bitharas J; Kessous R; Kogan L; Baloch T; Gotlieb WH; Yasmeen A
BMC Cancer; 2017 Sep; 17(1):638. PubMed ID: 28886696
[TBL] [Abstract][Full Text] [Related]
33. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
Oda K; Okada J; Timmerman L; Rodriguez-Viciana P; Stokoe D; Shoji K; Taketani Y; Kuramoto H; Knight ZA; Shokat KM; McCormick F
Cancer Res; 2008 Oct; 68(19):8127-36. PubMed ID: 18829572
[TBL] [Abstract][Full Text] [Related]
34. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
De Marco C; Laudanna C; Rinaldo N; Oliveira DM; Ravo M; Weisz A; Ceccarelli M; Caira E; Rizzuto A; Zoppoli P; Malanga D; Viglietto G
PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101
[TBL] [Abstract][Full Text] [Related]
35. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
[TBL] [Abstract][Full Text] [Related]
36. Revisiting the Clinical and Biologic Relevance of Partial PTEN Loss in Melanoma.
Giles KM; Rosenbaum BE; Berger M; Izsak A; Li Y; Illa Bochaca I; Vega-Saenz de Miera E; Wang J; Darvishian F; Zhong H; Osman I
J Invest Dermatol; 2019 Feb; 139(2):430-438. PubMed ID: 30148988
[TBL] [Abstract][Full Text] [Related]
37. NUAK2 Amplification Coupled with PTEN Deficiency Promotes Melanoma Development via CDK Activation.
Namiki T; Yaguchi T; Nakamura K; Valencia JC; Coelho SG; Yin L; Kawaguchi M; Vieira WD; Kaneko Y; Tanemura A; Katayama I; Yokozeki H; Kawakami Y; Hearing VJ
Cancer Res; 2015 Jul; 75(13):2708-15. PubMed ID: 25832654
[TBL] [Abstract][Full Text] [Related]
38. Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach.
Jiang W; Jia P; Hutchinson KE; Johnson DB; Sosman JA; Zhao Z
Oncotarget; 2015 Feb; 6(4):2496-508. PubMed ID: 25537510
[TBL] [Abstract][Full Text] [Related]
39. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
40. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
